From Yahoo Finance: 2025-06-05 20:59:00

HSBC upgraded Dr. Reddy’s Laboratories Limited (RDY) from Buy to Hold with a new price target of INR1,445, citing positive earnings potential and market standing. Analysts revised sales figures for FY2026 to FY2028, anticipating a surge in semaglutide sales and increasing competition for gRevlimid. The price target for RDY’s ADR was raised to $16.90. Dr. Reddy’s Laboratories is a global pharma company based in Hyderabad, India, operating through various segments. There is potential in investing in RDY, but some AI stocks may offer higher returns with limited downside risk.



Read more at Yahoo Finance: HSBC Upgrades Dr. Reddy’s Laboratories Limited (RDY) to Buy from Hold